Physician profile
Warren Joseph
NPI 1801907340
$529,381.13
in general payments reported to CMS, 2019-2025
14 companies · $96K in 2025
The $96K reported for 2025 was more than what 99% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103K · 2020: $7,937 · 2021: $39K · 2022: $82K · 2023: $122K · 2024: $79K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $189K · Travel and Lodging: $73K · Consulting Fee: $15K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Food and Beverage: $6,593 · Education: $39.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $189,155.00 |
| Travel and Lodging | $72,853.75 |
| Consulting Fee | $15,460.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,650.00 |
| Food and Beverage | $6,593.13 |
| Education | $39.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $355,947.53 | 2021-2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73,142.46 | 2019-2025 | Jublia |
| Melinta Therapeutics, LLC | $43,902.64 | 2019-2023 | Kimyrsa, Rezzayo, Orbactiv |
| Merck Sharp & Dohme LLC | $34,288.87 | 2019 | |
| Bone Support INC. | $13,548.00 | 2023-2025 | Ceramentbone Void Filler, Cerament G |
| Integra Lifesciences Corporation | $4,125.00 | 2019-2021 | |
| Reddress USA, INC. | $3,300.00 | 2021 | |
| Pfizer INC. | $500.00 | 2021 | |
| Kerecis Limited | $377.18 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Biosense Webster, INC. | $114.12 | 2024 | Qdot Micro Catheter, Carto 3 |
| Djo, LLC | $83.63 | 2024 | Cmf |
| Abbvie INC. | $29.74 | 2024-2025 | |
| Averitas Pharma INC. | $13.17 | 2023 | Qutenza |
| Advanced Oxygen Therapy INC. | $8.79 | 2024 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.